Filing Details
- Accession Number:
- 0001735276-24-000058
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-05-31 19:00:52
- Reporting Period:
- 2024-05-29
- Accepted Time:
- 2024-05-31 19:00:52
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1178670 | Alnylam Pharmaceuticals Inc. | ALNY | Pharmaceutical Preparations (2834) | 770602661 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1438226 | W Amy Schulman | 675 West Kendall Street Henri A. Termeer Square Cambridge MA 02142 | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2024-05-29 | 30,000 | $66.83 | 30,136 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-05-29 | 10,121 | $148.21 | 20,015 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-05-29 | 11,516 | $148.93 | 8,499 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-05-29 | 63 | $149.76 | 8,436 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | Disposition | 2024-05-29 | 30,000 | $0.00 | 30,000 | $66.83 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2024-07-01 | No | 4 | M | Direct |
Footnotes
- Reflects shares sold to cover option cost and tax obligations upon the option exercise pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on February 28, 2024. The 30,000 options exercised by the reporting person were due to expire on July 1, 2024.
- The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $147.62 to $148.60. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $148.63 to $149.52. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- This stock option was fully vested and exercisable as of July 1, 2017.
Billionaire Hedge Funds
